Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology

By Stephan Stern

Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen.

Listed in Datasets | publication by group NCL Protocols

Version 1.0 - published on 18 Oct 2022 doi:10.17917/W63A-GR02 - cite this

Licensed under these terms

Description

Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen and dose escalation strategy, and identify potential species differences. NCL’s in vivo experiments are tailored specifically to the individual nanoparticle under study.  As such, a standard experimental protocol cannot be generated.  Instead of a protocol, we offer the following general guidance for experimental design and data analysis. The following description is not a protocol and does not describe all of the relevant experimental parameters necessary to conduct the experiment. If you would like additional information, please feel free to contact us.

Content List

Cite this work

Researchers should cite this work as follows:

Tags

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.